Stephen K. Tyring - Concepedia

Author

Stephen K. Tyring

The University of Texas Medical Branch at Galveston ORCID

Also Known As

C S Thoming, S K Tyring, S Tyring, S. K. Tyring, S. Tyring, S.K Tyring, S.K. Tyring, STEPHEN K. TYRING, Stephen K Tyring, Stephen K. Tyring

681

Publications

25.3K

Citations

H-Index

209

Concepts

All Affiliations

The University of Texas Medical Branch at Galveston The University of Texas Health Science Center at Houston Center for Clinical Studies University of Houston Probity Medical Research

About

Stephen K. Tyring is an author at The University of Texas Medical Branch at Galveston specializing in medicine, pathology, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	102	6.7K
2	Health Sciences	7	7	1.3K
3	Social Sciences	7	7	193
4	Public Health	6	6	322
5	Natural Sciences	4	4	214

Stephen K. Tyring

218

Publications

19.3K

Citations

H-Index

Page 1

	Year	Citations
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G. Langley, Boni E. Elewski, Mark Lebwohl, New England Journal of Medicine	2014	1.9K
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Stephen K. Tyring, Alice B. Gottlieb, Kim Papp, The Lancet PsychiatryMedicineClinical TrialsDepressionClinical Dermatology	2005	1.1K
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Journal of the American Academy of Dermatology Autoimmune DiseaseSystemic TreatmentSevere PsoriasisPhase Iii TrialClinical Trials	2007	869
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Mark Lebwohl, Bruce Strober, Alan Menter, New England Journal of Medicine	2015	790
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes Lawrence R. Stanberry, Spotswood L. Spruance, Anthony L. Cunningham, New England Journal of Medicine	2002	788
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Kim Papp, Stephen K. Tyring, M. Lahfa, British Journal of Dermatology	2005	687
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, New England Journal of Medicine	2003	580
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Kristian Reich, Kim Papp, Andrew Blauvelt, The Lancet Tildrakizumab Versus PlaceboResurface 1Clinical TrialsPsoriatic ArthritisClinical Dermatology	2017	540
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis Kim Papp, Andrew Blauvelt, Michael Bukhalo, New England Journal of Medicine	2017	504
Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial Stephen K. Tyring, Rick A. Barbarash, James E. Nahlik, Annals of Internal Medicine	1995	495

Page 1